Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Immunic (IMUX – Research Report) on November 7 and set a price target ...

Jamie-Lynn Sigler had just started filming “The Sopranos” at 20 years old when she noticed numbness and tingling in her feet, as well as problems with bladder control, that worsened over time.

Different disease-modifying therapies (DMTs) have differing impacts on brain volume loss in patients with relapsing multiple sclerosis (RMS), according to a new study. People with multiple ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

The trials, which are expected to enroll about 2,100 adult patients with active RMS, are on track to be ... trial in patients with progressive multiple sclerosis (PMS), which we expect to release ...

Initiated the Phase 2 MoonStone trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial, to ...

Kesimpta was approved in August 2020 as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing ...

vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee ...

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis ... injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with ...